Kirk Neff, a cameraman used to filming princes and prime ministers, saw his career threatened by his inability to steady his ...
Boston Scientific (($BSX)) announced an update on their ongoing clinical study. Boston Scientific is conducting a study titled ‘Boston Scientific ...
Get these health and wellness insights emailed to you three times a week. With our LiveWell app and website, you can manage health and wellness for yourself and for everyone who counts on you.
HONOLULU — New imaging data may explain how transcutaneous afferent patterned stimulation (TAPS), a noninvasive, wearable therapy, works in patients with essential tremor (ET). In a small study that ...
Senate GOP leaders are again shaking up their strategy as they look for more ways to pressure Democrats to end a three-week stalemate over government funding — this time, with a vote that would keep ...
Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...
Praxis Precision Medicines surged after positive Essential3 data for ulixacaltamide in essential tremor, but tolerability issues limit enthusiasm. Ulixacaltamide demonstrated functional benefit, but ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Praxis' fortunes have ...
The FDA cleared an artificial intelligence (AI)-powered wristband (Felix NeuroAI) to treat upper-limb functional limitations in adults with essential tremor, device maker Fasikl announced. The ...
Praxis Precision Medicines shares more than doubled in premarket trading Thursday after the clinical-stage biopharmaceutical reported positive topline results from a pair of late-stage studies of its ...
Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. After brushing off a recommendation to end a phase 3 study earlier this year based on ...
Findings showed a statistically significant and clinically meaningful improvement in the mADL11 score at week 8 with ulixacaltamide vs placebo. Topline data were announced from two phase 3 trials ...